グレード
pharmaceutical primary standard
APIファミリー
nicergoline
メーカー／製品名
EDQM
アプリケーション
pharmaceutical (small molecule)
フォーマット
neat
保管温度
2-8°C
SMILES記法
[H][C@@]12Cc3cn(C)c4cccc(c34)[C@]1(C[C@@H](COC(=O)c5cncc(Br)c5)CN2C)OC
InChI
1S/C24H26BrN3O3/c1-27-13-17-8-21-24(30-3,19-5-4-6-20(27)22(17)19)9-15(12-28(21)2)14-31-23(29)16-7-18(25)11-26-10-16/h4-7,10-11,13,15,21H,8-9,12,14H2,1-3H3/t15-,21-,24+/m1/s1
InChI Key
YSEXMKHXIOCEJA-FVFQAYNVSA-N
類似した製品をお探しですか？ 訪問 製品比較ガイド
詳細
この製品は薬局方標準品です。発行元の薬局方により製造・供給されています。MSDSを含む製品情報などの詳しい情報は、発行元の薬局方のウェブサイトよりご確認ください。
アプリケーション
Nicergoline EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
包装
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
その他情報
Sales restrictions may apply.
シグナルワード
Warning
危険有害性情報
危険有害性の分類
Acute Tox. 4 Oral
保管分類コード
11 - Combustible Solids
WGK
WGK 3
引火点(°F)
Not applicable
引火点(℃)
Not applicable
Choose from one of the most recent versions:
試験成績書（COA）
Lot/Batch Number
Sorry, we don't have COAs for this product available online at this time.
If you need assistance, please contact カスタマーサポート
A Moretti
Arzneimittel-Forschung, 29(8a), 1213-1223 (1979-01-01)
The effects of 10-methoxy-1,6-dimethyl-ergoline-8 beta-methanol(5-bromonicotinate) (nicergoline, Sermion) on the energy metabolism in the animal CNS during and after cerebral hypoxia and ischemia have been studied by various authors by different methodological approaches. For this purpose both electrophysiological (EEG and cortically
Treatment of impaired cognition with nootropic drugs: nicergoline versus the state of the art.
R G Fariello
Functional neurology, 12(3-4), 221-225 (1997-05-01)
M Fioravanti et al.
The Cochrane database of systematic reviews, (4)(4), CD003159-CD003159 (2001-11-01)
Nicergoline is an ergot derivative currently in use in over fifty countries for more than three decades, for the treatment of cognitive, affective, and behavioral disorders of older people. It was initially considered as a vasoactive drug and mainly prescribed
Bengt Winblad et al.
Clinical drug investigation, 28(9), 533-552 (2008-08-01)
The ergot alkaloid derivative nicergoline became clinically available about 35 years ago in the 1970s. Nicergoline has a broad spectrum of action: (i) as an alpha(1)-adrenoceptor antagonist, it induces vasodilation and increases arterial blood flow; (ii) it enhances cholinergic and
A Moretti et al.
Arzneimittel-Forschung, 29(8a), 1223-1227 (1979-01-01)
10-Methoxy-1,6-dimethyl-ergoline-8 beta-methanol-(5-bromonicotinate) (nicergoline, Sermion) shows a strong alpha-blocking activity both in vitro and in vivo. Various studies (dog, cat, rabbit, rat, mouse, guinea-pig) show that nicergoline affects only slightly blood pressure and heart rate and increases the blood flow in
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら（テクニカルサービス）